Antibio tic resistance in upper respiratory trac t bac terial infec tions con tinues to inc rease . Since ora l fluoroquin olones have a uniqu e role as a seco nd-line therap y for respiratory infection s and as a therapy aga inst enteric organisms such as Pseudomo nas aeruginosa or Escheric hia coli. resistance to these antibiotics has co ntributed to the globa l concern that we are rapidly runni ng o ut of effective anti-infectives.
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In many locat ions in the United States and elsewhere, methici llin -resi stant Staphylo coccus au reus and Staphylococcus epidermidis are more common than the se nsitive stra ins of those species. Many of these multidrug -res istant staphy lococci are resis tant, by laboratory definiti ons, to ftuoroquin olones such as ciproftoxac in, ofloxacin, levoftoxacin, and moxifloxacin. P aeruginosa, a relatively common ca use of acute oti tis media with tympanosto my tubes (AOMT) and otitis externa, is increasingly resista nt to our mai nstay s of ora l therapy for infections ca used by this orga nism : ciproftoxacin and levofloxaci n.
As noted above, the freq uency of isolatio n of" resistant" gra m-posi tive organisms (staphylococci and streptococci) and certain gram-negative organisms (especially pse udom onads) fro m infec ted middle and externa l ea rs has increased sig nificantly in the past 5 yea rs, j ust as their isolation rate fro m all ot her sites has increase d. This has led a num ber of aut hors to sugges t that when selecti ng an ototopical antibiotic, one should carefully consider the result s of laboratory antibiotic sen sitivity testing . While such prudence might , on the surface, appear appropriate, the suggestio n is mostly wrong.
Antibiotic efficacy
For antibio tics to be effec tive, they must ge nerally exceed the conce ntratio ns req uired to inhibi t the target orga nism(s) at the site of infectio n. Microbiologists ofte n refer to this as "meeti ng the pharmacok inetic/pharmacody namic (PKl PD) parameters that are nec essary for antibacterial therapy." In this setting, and as exp laine d in recent antimicrobial guidelines, the term pharmacokin etics refe rs to factors that contribute to tissue or serum level s, while pharmacodynamics relate s to the intri nsic ac tivities of the antibiotic aga inst the bacteria.
To assess the effectiveness of give n antibiotics again st an orga nism, laboratories usually establish an in vitro minimum inhibitory concentration (MIC) and then interpret those values so they ca n report the organ ism as being sensitive. intermediate. or re sistantto the antibiotic(s) tested.The import ant point is that the laboratory definiti ons of sensitive and resistant app ly to the levels of antibiotics that can be achieved by systemic admin istra tion. Th ey do not app ly to the dra matically higher co ncentrations that are presen t Clinical failure of ototopi cals is not related to antibiotic resistance per se but is most often attributable to poor drug delivery, [which is] related to failure to adequ ately remove copious amounts of ear canal purulen ce. in top ical pre para tions. Th is holds true for the classes of antibio tics (quinolones and ami noglycosides) for which the prevalent mechanisms of resis tance confer relative degrees of resistance, as opposed to those mechanism s (e.g., beta-Iactamase destruction of lactams) that ca use an all-or-none type of resistance. For example, systemic admini stration offt uoroquinolones such as ciprofloxacin or levoftoxacin commonly results in tissue levels that range fro m I t04 ug/rnl, while "resistant" strains ofstaphylococci or pse udo monads are often inhibited only at antibio tic concent rati ons (MICs) rang ing from 8 to 64 ug/rnl. Obviously, the tiss ue levels are inadequat e for effect ive therapy. Commonly used quinolone oto topica ls, on the other hand, typically contain 3,000 ug/m l of the antibiotic .
Given the above considerations, at what MIC does an organism become resistant to ototopical preparations of ciprofloxacin or oflox acin ? In otitis externa (if we assume reasonable removal of ear canal debris and the use of wick s when appropriate), the MIC would be close to the concentration in the ear drop, since that is the conce ntration that reaches the orga nisms. The concentration of the antibiotic in the middl e ear or ma stoid with otic prep aration s inAOMT is a more complex issue . A number of factors migh t affect the concentration achi eved behind the tympanic membrane (tab le) . Not surprisingly, the measured middle ear antibiotic concentration s in patie nts with ototopically treatedAOMT have been fou nd to range widely. For insta nce , Ohyama et al reported middle ear levels of ofloxaci n tha t ranged from 389 to 2,850 ug/rnl .' As MICs are usua lly tes ted in a series of two-fo ld dil ution s, I propose that we co nsider the d ilut ion clo ses t to the lowe st measured concentration as the breakpoint for defining resistance. So for preparation s that contain 3,000 ug/ml of ciprofloxacin, strai ns with mea sured MICs of256 ug/m l or gre ater might rea sonably be con sidered resistant, and therapy might fai l as a con sequ ence of inadequate PK/PD performa nce . Ofloxacin otic contains a lesser amo unt of active antib iotic because the racemic mixture of ofloxaci n co ntains only 1,500 ug/rnl of the active levo isomer; therefore organi sm s migh t be con sidered to be potentially resistant if the MIC is 128 ug/ml, The large st collection of (potential) pathogens isolated from external otiti s?or AOMT3has been accumulated and analyzed by Alcon Laboratori es du ring cl inical trial s of their otic preparations. Of the thou sand s of isol ates, less than 0.1 % had MIC s of at least 256 ug/ml . 14· Volume 86 • Suppl 1 Ant ib iot ic resistance and treatment f ailure Two final points should be co nsidered by clin icia ns who ma nage AOM T and who are interested in these highl y resistant strains:
• Mo st clinical laboratories do not perform MIC endpoi nt testing. Therefore, the y often report an MIC as, for example, > 8 pg/ml or > 64 ug/ml. As a result, the clin ician is left wondering whether the MIC might actually be 128 or 256 ug/ml.
• Clinical failures with ototopicals occur more often than the rare occ urre nce of tru ly high res istance would predict. I bel ieve these fai lures are almos t always attri butable to inadequ ate delivery of the otic drops to the middle ear. I have admitted to the hospital a sm all number of such "clinical failures ." When our staff administered the drops as (we thought) we had instructed the famil y to do , the otorrhea promptly ceased . C linical failure of ototopicals is not related to antibiotic resist ance per se but is mo st oft en attributable to poor drug delivery, related to fai lure to adequately remove copious amounts of ear canal purulence, or to ot her de livery fail ure s. Oto lary ngologists typically emp loy or reco mmend .one of fo ur meth od s to remove ear ca na l puru lence (us ually on a dai ly basis): (I) ace tic irr igations, (2) placement of ea r ca nal wicks, (3) suction, and (4) dry mopping. Inadequ ate drop volume and a lack of tragal pumping may also impede midd le ear delivery. Recognition of the importance of the se mechanical issue s by primary care cli nic ian s and compliance by the families is, however, less than optimal.
In summary, clinical resistance among the bac teria assoc iated with AOMT, chronic supp ura tive otitis med ia, or otitis exte rna is almost no nexis tent when oto topical quinolone s are used appropriate ly. The laboratory definitions of resistance to these antibio tics, in general, are not pertinent to topical preparations. Further, unlike systemically administered antibiotics, the se topical agents are highly un likel y to incre ase resistance rates of target and nontarget bacteria of interest, since they do not target the populations of the pat hogen s at the primary site(s) where they typically colonize.
